furosemide has been researched along with Alzheimer Disease in 7 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks." | 1.62 | 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease. ( Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M, 2021) |
| "The multifactorial nature of Alzheimer's disease (AD) is a reason for the lack of effective drugs as well as a basis for the development of "multi-target-directed ligands" (MTDLs)." | 1.62 | Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. ( Angeloni, C; Bartolini, M; Bergamini, C; Bolognesi, ML; Chantegreil, F; de Camargo Nascente, L; de Melo Viana Teixeira, S; Freschi, M; Hrelia, S; Malaguti, M; Nachon, F; Prchal, L; Rossi, M; Salerno, A; Soares Romeiro, LA; Soukup, O, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Salahuddin, P | 1 |
| Fatima, MT | 1 |
| Abdelhameed, AS | 1 |
| Nusrat, S | 1 |
| Khan, RH | 1 |
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 1 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Janockova, J | 2 |
| Soukup, O | 3 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Saudi, MNS | 1 |
| Bartolini, M | 2 |
| Belal, ASF | 1 |
| Mezeiova, E | 1 |
| Andrys, R | 1 |
| Kobrlova, T | 1 |
| Muckova, L | 1 |
| Pejchal, J | 1 |
| Simunkova, M | 1 |
| Handl, J | 1 |
| Micankova, P | 1 |
| Capek, J | 1 |
| Rousar, T | 1 |
| Hrabinova, M | 1 |
| Nepovimova, E | 1 |
| Marco-Contelles, JL | 1 |
| Valko, M | 1 |
| Korabecny, J | 1 |
| Rossi, M | 1 |
| Freschi, M | 1 |
| de Camargo Nascente, L | 1 |
| Salerno, A | 1 |
| de Melo Viana Teixeira, S | 1 |
| Nachon, F | 1 |
| Chantegreil, F | 1 |
| Prchal, L | 1 |
| Malaguti, M | 1 |
| Bergamini, C | 1 |
| Angeloni, C | 1 |
| Hrelia, S | 1 |
| Soares Romeiro, LA | 1 |
| Bolognesi, ML | 1 |
| Wang, Z | 2 |
| Wang, Y | 1 |
| Pasangulapati, JP | 1 |
| Stover, KR | 1 |
| Liu, X | 1 |
| Schier, SW | 1 |
| Weaver, DF | 2 |
| Vilekar, P | 1 |
| Huang, J | 1 |
| Ros Forteza, FJ | 1 |
1 review available for furosemide and Alzheimer Disease
| Article | Year |
|---|---|
Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Topics: Alzheimer Disease; Amyloid; Animals; Humans; Molecular Structure; Parkinson Disease; Prion Diseases; | 2016 |
6 other studies available for furosemide and Alzheimer Disease
| Article | Year |
|---|---|
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Anacardium; Binding Sites; Butyrylcholinesterase; Catalytic | 2021 |
Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents; Dose-Response Relationship, Drug | 2021 |
Furosemide as a Probe Molecule for the Treatment of Neuroinflammation in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Endoplasmic Reticulum Chaperone BiP; Furosemide; Humans; M | 2020 |
Alzheimer disease triggered by reversible posterior leukoencephalopathy syndrome.
Topics: Acetaminophen; Aged; Alzheimer Disease; Analgesics, Non-Narcotic; Antihypertensive Agents; Captopril | 2020 |